Heterocyclyl anthracyclinone derivatives
US6316451A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2000 |
| Grant date | Nov 13, 2001 |
| Priority date | — |
| Expiry date | Sep 26, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D277/42
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A compound of formula (1) wherein R.sub.1 is hydrogen, hydroxy, a group of formula OR.sub.5 wherein R.sub.5 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.3 -C.sub.8 cycloalkyl, halogen, amino which may be unsubstituted or mono or disubstituted by C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, aralkyl, acyl or trifluoroacetyl; R.sub.2 is hydrogen, hydroxy, a group NR.sub.6 R.sub.7 wherein R.sub.6 and R.sub.7 independently represent hydrogen, an optionally substituted C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.3 -C.sub.8 cycloalkyl or, taken together with the nitrogen atom, represent an optionally substituted C.sub.3 -C.sub.8 heterocyclic ring; R.sub.3 is hydrogen, hydroxy, R.sub.4 is a 2-substituted thiazolyl or imidazolyl system and the pharmaceutically acceptable salt thereof, is useful in the treatment of amyloidosis. Processes for the preparation and pharmaceutical compositions are also described. ##STR1##
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.